Samalin Investment Counsel LLC Lowers Holdings in Novo Nordisk A/S (NYSE:NVO)

Samalin Investment Counsel LLC cut its position in Novo Nordisk A/S (NYSE:NVO) by 6.2% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,059 shares of the company’s stock after selling 470 shares during the quarter. Samalin Investment Counsel LLC’s holdings in Novo Nordisk A/S were worth $607,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also bought and sold shares of NVO. Commerce Bank lifted its stake in Novo Nordisk A/S by 16.0% in the 3rd quarter. Commerce Bank now owns 32,534 shares of the company’s stock worth $3,874,000 after purchasing an additional 4,489 shares in the last quarter. Citizens Financial Group Inc. RI lifted its stake in Novo Nordisk A/S by 1.9% in the 3rd quarter. Citizens Financial Group Inc. RI now owns 14,301 shares of the company’s stock worth $1,703,000 after purchasing an additional 263 shares in the last quarter. Massachusetts Financial Services Co. MA lifted its stake in Novo Nordisk A/S by 2.8% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 79,660 shares of the company’s stock worth $9,485,000 after purchasing an additional 2,166 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its stake in Novo Nordisk A/S by 16.5% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 204,583 shares of the company’s stock worth $24,360,000 after purchasing an additional 28,988 shares in the last quarter. Finally, Eagle Asset Management Inc. lifted its stake in Novo Nordisk A/S by 10.4% in the 3rd quarter. Eagle Asset Management Inc. now owns 17,893 shares of the company’s stock worth $2,131,000 after purchasing an additional 1,680 shares in the last quarter. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several analysts have recently weighed in on the stock. Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research report on Monday, January 6th. BNP Paribas upgraded shares of Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. BMO Capital Markets lowered their price objective on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a research report on Monday, December 23rd. Kepler Capital Markets upgraded shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research report on Thursday, March 13th. Finally, UBS Group upgraded shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research report on Wednesday, January 8th. Three research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $145.25.

Novo Nordisk A/S Price Performance

Shares of NYSE:NVO opened at $76.88 on Friday. The stock has a market cap of $344.98 billion, a PE ratio of 23.37, a PEG ratio of 0.90 and a beta of 0.42. The company’s fifty day moving average is $83.34 and its 200 day moving average is $100.98. Novo Nordisk A/S has a 52 week low of $73.80 and a 52 week high of $148.15. The company has a quick ratio of 0.55, a current ratio of 0.74 and a debt-to-equity ratio of 0.62.

Novo Nordisk A/S (NYSE:NVO) last issued its earnings results on Wednesday, February 5th. The company reported $0.91 EPS for the quarter, topping analysts’ consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. Research analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Increases Dividend

The company also recently declared a semi-annual dividend, which will be paid on Tuesday, April 8th. Shareholders of record on Monday, March 31st will be issued a $0.7874 dividend. This represents a yield of 1.2%. The ex-dividend date of this dividend is Monday, March 31st. This is a positive change from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. Novo Nordisk A/S’s dividend payout ratio (DPR) is 47.72%.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.